Literature DB >> 9817475

Usefulness of losartan, captopril, and furosemide in preventing nitrate tolerance and improving control of unstable angina pectoris.

G Cotter1, E Metzkor-Cotter, E Kaluski, A Blatt, I Litinsky, Y Baumohl, Y Moshkovitz, Z Vered, R Zaidenstein, A Golik.   

Abstract

Sixty consecutive normotensive patients with unstable angina pectoris, who were on continuous intravenous isosorbide dinitrate (ISDN) treatment and had not previously received angiotensin II receptor antagonists, angiotensin-converting enzyme (ACE) inhibitors, or diuretics were randomly assigned to treatment groups receiving intravenous ISDN for 72 hours. No additional treatment was given to group A (n = 15). Captopril, in a test dose of 6.25 mg, and followed by 12.5 mg 3 times daily for 24 hours and 25 mg 3 times daily for the next 24 hours, was given to group B (n = 15). The same dose of captopril plus 40 mg of furosemide in the morning were given to group C (n = 15). Losartan, in a single dose of 25 mg/day and increased to 50 mg after 24 hours was given to group D (n = 15). Nitrate tolerance was evaluated at 24-hour intervals at trough levels of each of the drugs by administering intravenous ISDN (1 mg bolus dose every 4 minutes) and recording the total ISDN test dose required to decrease the mean arterial blood pressure by > or =10%. Treatment with continuous ISDN only (group A) induced nitrate tolerance. The ISDN (mean +/- SD) test dose was 3.5 +/- 1.8 mg at baseline, increasing to 4.9 +/- 2.4 mg at 24 hours, and 8.0 +/- 3.0 mg at 48 hours. The addition of increasing doses of captopril to the continuous ISDN treatment (group B) completely prevented nitrate tolerance. Losartan, however, did not attenuate nitrate tolerance at 24 hours and attenuated it only partially at 48 hours. The addition of furosemide to captopril had no further effect on nitrate tolerance. Of 15 patients in group A (ISDN only), 4 (27%) experienced recurrent ischemic events requiring urgent coronary catheterization. No such events were recorded in group B (captopril), but did occur in 1 patient in each of group C (captopril plus furosemide) and D (losartan) (p = 0.083). Thus, the addition of captopril to the ISDN treatment regimen prevented tolerance to nitrates and improved angina control with apparent safety. Losartan also decreased nitrate tolerance, although to a lesser extent, and also improved angina control. The addition of furosemide to captopril conferred no further benefit.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9817475     DOI: 10.1016/s0002-9149(98)00548-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers.

Authors:  W J Elliott
Journal:  Curr Hypertens Rep       Date:  2000-08       Impact factor: 5.369

2.  A Pilot Study of Perioperative External Circumferential Cryoablation of Human Renal Arteries for Sympathetic Denervation.

Authors:  Claes Forssell; Niclas Bjarnegård; Fredrik H Nyström
Journal:  Vasc Specialist Int       Date:  2020-09-30

Review 3.  Organic nitrate metabolism and action: toward a unifying hypothesis and the future-a dedication to Professor Leslie Z. Benet.

Authors:  Nathaniel A Page; Ho-Leung Fung
Journal:  J Pharm Sci       Date:  2013-05-13       Impact factor: 3.534

4.  Dissociation between superoxide accumulation and nitroglycerin-induced tolerance.

Authors:  Pei-Suen Tsou; Vamsi Addanki; Ho-Leung Fung
Journal:  J Pharmacol Exp Ther       Date:  2008-07-24       Impact factor: 4.030

Review 5.  Nitrate tolerance and the links with endothelial dysfunction and oxidative stress.

Authors:  Katherine E Fayers; Michael H Cummings; Kenneth M Shaw; David W Laight
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 6.  Organic nitrates and nitrate resistance in diabetes: the role of vascular dysfunction and oxidative stress with emphasis on antioxidant properties of pentaerithrityl tetranitrate.

Authors:  Matthias Oelze; Swenja Schuhmacher; Andreas Daiber
Journal:  Exp Diabetes Res       Date:  2010-12-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.